Bayer Reports P-III (REVEAL) Trial Data on Iodine 124 Evuzamitide to Diagnose Cardiac Amyloidosis

Why It Matters

Accurate, non‑invasive diagnosis of cardiac amyloidosis can accelerate treatment initiation and improve patient outcomes, positioning Bayer to capture a growing market for amyloid‑targeted therapies.

Key Takeaways

• Phase III REVEAL trial enrolled 170 patients with suspected cardiac amyloidosis
• I‑124 evuzamitide met primary sensitivity and specificity endpoints
• Breakthrough Therapy Designation granted by FDA for PET imaging
• Orphan Drug status secured for AL and ATTR amyloidosis in US/EU
• Bayer will discuss data with regulators and seek FDA approval

Pulse Analysis

Cardiac amyloidosis, a progressive infiltrative disease, affects an estimated 100,000 patients in the United States and carries a median survival of less than three years once symptomatic. Early detection is critical, yet current diagnostic pathways rely on invasive endomyocardial biopsy or indirect imaging such as echocardiography and cardiac MRI, which can miss early deposits. A reliable, non‑invasive PET tracer that directly visualizes amyloid deposits would therefore fill a major clinical gap and enable timely therapeutic intervention. Moreover, accurate staging informs eligibility for emerging monoclonal antibody treatments that have shown survival benefit.

Bayer’s investigational I‑124 evuzamitide, administered intravenously, was evaluated in the Phase III REVEAL study involving 170 adults with suspected cardiac amyloidosis. The trial used PET/CT imaging and a visual readout to compare the tracer against standard‑of‑care clinical diagnosis, achieving prespecified sensitivity and specificity thresholds. The compound already holds FDA Breakthrough Therapy Designation and orphan‑drug status for both AL and ATTR amyloidosis in the United States and European Union, positioning it for accelerated regulatory review. Safety data were consistent with prior Phase II studies, showing no serious adverse events attributable to the tracer.

If approved, I‑124 evuzamitide could become the first PET‑based definitive test for cardiac amyloidosis, streamlining patient pathways and potentially expanding the market for disease‑modifying therapies. Bayer’s imaging portfolio would gain a differentiated asset, complementing its broader cardiovascular and oncology pipeline. Analysts anticipate that regulatory submission later this year could translate into U.S. sales exceeding $200 million within five years, assuming adoption by major academic centers and community hospitals alike. The tracer’s ability to differentiate AL from ATTR subtypes may also guide personalized therapeutic choices, further enhancing its clinical value.